Globe on Big Pharma R&D Failure
3 Comments
Law Bytes
Episode 63: Ontario Privacy Commissioner Patricia Kosseim on the COVID Alert App
Recent Posts
The LawBytes Podcast, Episode 63: Ontario Privacy Commissioner Patricia Kosseim on the COVID Alert App 
The LawBytes Podcast, Episode 62: Colin Bennett on What the Schrems II Decision Means for Global Data Transfers and Canadian Privacy Law 
Why I Installed the COVID Alert App 
A Quarter-Billion Dollar Bag of Beans: Responding to Ken Whyte’s Attack on Library Book Loans 
The LawBytes Podcast, Episode 61: Senator James Cowan on the Extraordinary Battle for a Genetic Anti-Discrimination Law in Canada
So, repeal C-22
If the drug companies can renege, then so can the goodies that were given to them be taken away.
Seems pretty straightforward to me.
Why aren’t there such things as charitable venture capital orgs? After-all many charities (eg JDRC) contribute to for-profit orgs. It seems to me that charitable donations would go much further if the beneficiaries of donations (R&D orgs) had to contribute returns back to charities. The role of charities like JDRC then would be to encourage R&D firms to take greater risks.
Hey, Michael! Don’t be so ungrateful or narrow minded. What about the bevy of busy lawyers who make gazillions every year doing “research” on their endless litany of pharmaceutical patent cases in the courts? What about all that useful literature and education directed at the medical profession, so that they are better informed about what pills their patients should pop? That takes a lot of “research and development”. And what about all the consumer focus group “research†that goes into those cute Cialis TV commercials?